Biome Australia Reports Strong Q3 Growth and Expands Internationally

An update from Biome Australia Ltd ( (AU:BIO) ) is now available.

Biome Australia Limited reported a strong financial performance for the third quarter of 2025, with a sales revenue increase of 41% year-over-year, reaching $4.51 million. The company achieved a gross margin of 61% and recorded a net operating cash inflow of $123k, with cash receipts up 61% compared to the previous corresponding period. Biome is on track to report its first full-year net profit for FY25, marking a significant milestone in its growth trajectory. The company’s strategic expansion into international markets and the launch of its new product range, Activated Therapeutics™, are expected to further bolster its market position and stakeholder value.

More about Biome Australia Ltd

Biome Australia Limited is a microbiome health company that focuses on developing and distributing health products. The company operates in both local and international markets, expanding its presence by adding new products to retail pharmacy partners and signing new health retailers in countries such as Canada, Ireland, the United Kingdom, and New Zealand.

YTD Price Performance: -25.42%

Average Trading Volume: 314,820

Technical Sentiment Signal: Hold

Find detailed analytics on BIO stock on TipRanks’ Stock Analysis page.